Postpolio syndrome. G14 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM G14 became effective on October 1, 2018. This is the American ICD-10-CM version of G14 - other international versions of ICD-10 G14 may differ.
Complex regional pain syndrome I, unspecified 1 G90.50 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2019 edition of ICD-10-CM G90.50 became effective on October 1, 2018. 3 This is the American ICD-10-CM version of G90.50 - other international versions of ICD-10 G90.50 may differ.
G14 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM G14 became effective on October 1, 2021. This is the American ICD-10-CM version of G14 - other international versions of ICD-10 G14 may differ.
G14 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM G14 became effective on October 1, 2021. This is the American ICD-10-CM version of G14 - other international versions of ICD-10 G14 may differ. A type 1 excludes note is a pure excludes.
ICD-10 code E03. 1 for Congenital hypothyroidism without goiter is a medical classification as listed by WHO under the range - Endocrine, nutritional and metabolic diseases .
ICD-10 code H91. 90 for Unspecified hearing loss, unspecified ear is a medical classification as listed by WHO under the range - Diseases of the ear and mastoid process .
Having sensorineural hearing loss means there is damage either to the tiny hair cells in your inner ear (known as stereocilia), or to the nerve pathways that lead from your inner ear to the brain. It normally affects both ears. Once you develop sensorineural hearing loss, you have it for the rest of your life.
3.
Pendred syndrome (PDS) is one of the most frequent forms of syndromic genetic deafness. Although precise prevalence is unknown, PDS may account for up to 7.5% of cases of congenital hearing loss.
Considerable phenotypic variability is found even within families. The main presenting clinical sign is prelingual sensorineural deafness, although occasionally the hearing loss develops later in childhood. The degree of hearing loss is variable: it can be mild-to-moderate and progressive in some patients, and severe-to-profound in others.
Biallelic or double heterozygous genetic mutations are identified in about half of patients: biallelic mutations in SLC26A4 (7q31), or double heterozygous mutations in SLC26A4 and FOXI1 (5q34), or in SLC26A4 and KCNJ10 (1q23.2).
The diagnosis of PDS is based on the presence of hearing impairment, temporal bone anomalies of the inner ear, and an abnormal perchlorate discharge test (if available) or goiter. The anomalies can be diagnosed by computed tomography (CT) and/or magnetic resonance imaging (MRI), although the former provides better resolution of bony changes.
The differential diagnosis includes congenital cytomegaloviral infection (cCMV), BOR syndrome, and deafness at the DFNX2 locus ( POU3F4 ).
Prenatal testing for at-risk pregnancies is possible when mutations in a family are known.
PDS follows an autosomal recessive pattern of inheritance. Genetic counseling should be provided to affected families.
The 2022 edition of ICD-10-CM I67.83 became effective on October 1, 2021.
A disorder characterized by headaches, mental status changes, visual disturbances, and seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition.